- Home
- ELWS vs SNGX Comparison
ELWS vs SNGX Comparison
Compare ELWS & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- SNGX
- Stock Information
- Founded
- ELWS 2018
- SNGX 1987
- Country
- ELWS Japan
- SNGX United States
- Employees
- ELWS N/A
- SNGX N/A
- Industry
- ELWS
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- SNGX Health Care
- Exchange
- ELWS Nasdaq
- SNGX Nasdaq
- Market Cap
- ELWS 6.2M
- SNGX 6.1M
- IPO Year
- ELWS 2023
- SNGX 1987
- Fundamental
- Price
- ELWS $2.18
- SNGX $2.21
- Analyst Decision
- ELWS
- SNGX
- Analyst Count
- ELWS 0
- SNGX 0
- Target Price
- ELWS N/A
- SNGX N/A
- AVG Volume (30 Days)
- ELWS 11.9K
- SNGX 29.1K
- Earning Date
- ELWS 03-03-2025
- SNGX 05-09-2025
- Dividend Yield
- ELWS N/A
- SNGX N/A
- EPS Growth
- ELWS N/A
- SNGX N/A
- EPS
- ELWS N/A
- SNGX N/A
- Revenue
- ELWS $2,292,406.00
- SNGX $119,371.00
- Revenue This Year
- ELWS N/A
- SNGX N/A
- Revenue Next Year
- ELWS N/A
- SNGX N/A
- P/E Ratio
- ELWS N/A
- SNGX N/A
- Revenue Growth
- ELWS 404.13
- SNGX N/A
- 52 Week Low
- ELWS $1.04
- SNGX $1.83
- 52 Week High
- ELWS $8.68
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- ELWS 47.54
- SNGX 46.98
- Support Level
- ELWS $2.01
- SNGX $2.25
- Resistance Level
- ELWS $2.39
- SNGX $2.41
- Average True Range (ATR)
- ELWS 0.23
- SNGX 0.11
- MACD
- ELWS 0.06
- SNGX -0.01
- Stochastic Oscillator
- ELWS 55.71
- SNGX 56.45
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).